Cooper Companies (NASDAQ:COO) Price Target Lowered to $66.00 at UBS Group

Cooper Companies (NASDAQ:COO) had its target price cut by equities researchers at UBS Group from $75.00 to $66.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical device company’s stock. UBS Group’s price objective points to a potential upside of 22.41% from the company’s current price.

A number of other research analysts also recently weighed in on COO. Citigroup reissued a “neutral” rating on shares of Cooper Companies in a research note on Thursday. Weiss Ratings reiterated a “sell (d)” rating on shares of Cooper Companies in a report on Friday, September 4th. JPMorgan Chase & Co. dropped their price target on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a research report on Friday, June 5th. The Goldman Sachs Group set a $61.00 price objective on shares of Cooper Companies in a research note on Wednesday, May 27th. Finally, Mizuho set a $85.00 price objective on shares of Cooper Companies and gave the stock an “outperform” rating in a report on Thursday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Cooper Companies currently has a consensus rating of “Hold” and an average target price of $74.33.

Cooper Companies Trading Down 15.1%

Shares of NASDAQ:COO opened at $53.92 on Thursday. The stock has a market capitalization of $10.52 billion, a PE ratio of 45.22, a P/E/G ratio of 1.77 and a beta of 0.82. Cooper Companies has a 1 year low of $51.01 and a 1 year high of $89.83. The firm has a fifty day moving average price of $72.42 and a 200 day moving average price of $70.02. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the prior year, the business posted $0.49 earnings per share. The business’s quarterly revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Analysts expect that Cooper Companies will post 4.63 EPS for the current fiscal year.

Cooper Companies declared that its board has initiated a stock repurchase program on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to reacquire up to 22.7% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Cooper Companies

Hedge funds have recently made changes to their positions in the stock. Root Financial Partners LLC increased its stake in Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 162 shares during the period. Avalon Trust Co acquired a new stake in shares of Cooper Companies during the 2nd quarter worth approximately $25,000. SJS Investment Consulting Inc. increased its position in shares of Cooper Companies by 107.5% during the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 187 shares during the period. Elevation Wealth Partners LLC increased its position in shares of Cooper Companies by 1,136.4% during the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 375 shares during the period. Finally, Continuum Advisory LLC acquired a new position in shares of Cooper Companies in the second quarter valued at $30,000. Institutional investors own 24.39% of the company’s stock.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: COO reported fiscal Q3 adjusted EPS of $1.15, above the $1.11-$1.12 analyst consensus. GAAP EPS was $2.24, helped by a $307.2 million benefit from the favorable completion of a U.K. tax examination. Free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded the share-repurchase authorization from $2 billion to $3 billion, potentially allowing repurchases of up to 22.7% of outstanding shares. Management also said it remains open to strategic alternatives that could create shareholder value. CooperCompanies Completes Strategic Review
• Neutral Sentiment: Third-quarter revenue rose roughly 1% year over year to $1.066 billion, with CooperVision revenue flat at $717 million and CooperSurgical revenue up 2% to $349.2 million. The results show continued profitability but limited underlying growth.
• Negative Sentiment: Revenue missed the approximately $1.10 billion consensus estimate, while fiscal 2026 adjusted EPS guidance was cut to $4.51-$4.55 from expectations near $4.63. Fourth-quarter EPS guidance of $1.05-$1.09 also trails the roughly $1.20 consensus. Analysts Lower Forecasts Following Q3 Results
• Negative Sentiment: CooperCompanies ended its strategic review by retaining CooperSurgical because potential offers were not attractive enough. Investors appear disappointed that the company will not receive sale proceeds, amid valuation pressure from a new non-hormonal IUD competitor and recent fertility-litigation costs.
• Negative Sentiment: Analysts responded by lowering price targets, including Needham to $73 from $86 and Bank of America to $65 from $80. Bank of America maintained a neutral rating, while the forecast reductions reinforced concerns about near-term growth.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.